Here are four things to know:
1. VANTRELA ER is intended to manage severe pain that may require long-term opioid treatment.
2. VANTRELA ER is an extended-release formulation of hydrocodone bitartrate with Teva’s proprietary abuse deterrence technology.
3. The committees also voted that, if approved, Teva Pharmaceutical’s should label the medication an “abuse-deterrent product.”‘
4. While the FDA is not bound by the committees, it will take their decision into consideration.
More articles on ASC quality:
Planetree selects Laser Spine Institute as 1st ASC to participate in patient-centered outcomes research project: 5 points
US surgeons use Stryker’s SurgiCount Safety Sponges in 10M procedures: 5 notes
More than 1k infants linked to Zika & microcephaly — 5 takeaways
